Journal profile · Biochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology
EBioMedicine
ISSN 2352-3964 · Elsevier BV · Netherlands
EBioMedicine: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 11.11; fully open access; APC about USD 6,810; median 183 days to acceptance (109 articles, last 24 months); 548 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
EBioMedicine is published by Elsevier BV and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are SARS-CoV-2 and COVID-19 Research, Gut microbiota and health and COVID-19 Clinical Research Studies, together about 22.4% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
For more information on the journal see https://www.thelancet.com/journals/ebiom/home eBioMedicine is the premium gold open access venue for translational biomedical research. The journal publishes original research that elucidates, or aims to modify, disease pathways and mechanisms—with the goal of advancing our knowledge in any biomedical discipline with relevance to human health as well as relevant reviews, commentaries, and opinion pieces. The journal prioritises papers investigating the basic determinants of human health and disease, the discovery and characterization of new therapeutic targets and treatments, and the identification of biomarkers and diagnostic tools which may help researchers and clinicians better understand and monitor disease.eBioMedicine covers the whole spectrum of biomedical research, from preclinical studies with clear human relevance, through to proof-of-concept studies and clinical trials. The journal aspires to catalyse dialogue and collaboration between basic scientists, clinical researchers and healthcare professionals, enhance the accessibility and applicability of basic research findings for health professionals, and promote a better understanding of clinical challenges for biomedical researchers.
From the journal's Aims & Scope
Research area (LetPub): Biochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology
Main research topics OpenAlex counts of recent articles; shares are approximate
- SARS-CoV-2 and COVID-19 ResearchMedicine8.3%
- Gut microbiota and healthBiochemistry, Genetics and Molecular Biology7.4%
- COVID-19 Clinical Research StudiesMedicine6.7%
- HIV Research and TreatmentImmunology and Microbiology5.8%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology4.9%
- Cancer Immunotherapy and BiomarkersMedicine4.5%
- Genetic Associations and EpidemiologyBiochemistry, Genetics and Molecular Biology4.2%
- Immune Cell Function and InteractionImmunology and Microbiology4.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Medicine, Research & Experimental | Zone 1 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Medicine, Research & Experimental | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Medicine, Research & Experimental | Zone 1 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 11.11LetPub ·
- Impact factor (publisher)
- 11.2Publisher website ·
- CiteScore 2026-06
- 19.1LetPub ·
- CiteScore (publisher)
- 19.1Publisher website ·
- SJR 2026-06
- 3.74LetPub ·
- SNIP 2026-06
- 2.37LetPub ·
- h-index
- 37LetPub ·
- h-index
- 186OpenAlex ·
- i10-index
- 4,067OpenAlex ·
- 2-year mean citedness
- 10.45OpenAlex ·
- Self-citation rate
- 0.9%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 460LetPub ·
Articles by year OpenAlex count · 6,411 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 387 | 387 | 325 |
| 2025 | 548 | 548 | 4,346 |
| 2024 | 586 | 586 | 11,220 |
| 2023 | 508 | 508 | 18,259 |
| 2022 | 617 | 617 | 26,699 |
| 2021 | 614 | 614 | 25,772 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
183 daysMedian, submission to acceptance · P25–P75 135 days – 257 days
- Acceptance to online
- median 16 days (109 articles)
- Submission to online
- median 201 days
- Sample
- 109 articles with submission and acceptance dates (1,091 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 5 weeksLetPub ·
- Submission to first decision
- 2 daysPublisher website ·
- Submission to acceptance
- 161 daysPublisher website ·
- Submission to publication (journal-reported)
- about 27 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 6,810 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 5,780 / EUR 5,410 / GBP 4,630 / JPY 716,890 | — | — | |
| LetPub | USD 5,000 | Yes | — | |
| Publisher website | USD 6,810 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteOpen access
- Open access Open Access
Article Publishing Charge (APC): USD 6,810 (excluding taxes). This journal is taking part in the GPOA program.Review this journal’s open access policy.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier BV
- Country or region
- Netherlands
- Language
- English
- ISSN
- 2352-3964
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗LetPub
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about EBioMedicine
What CAS zone is EBioMedicine in?
In the 2025 upgraded edition of the CAS Journal Ranking, EBioMedicine is in Zone 1 of Medicine, and in Zone 1 of the minor category Medicine, Research & Experimental; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of EBioMedicine?
The latest impact factor listed by LetPub is 11.11; CiteScore 19.1, h-index 186.
How long does peer review take at EBioMedicine?
Based on the dates recorded on 109 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 183 days (interquartile range 135–257 days); authors report an average review time of about 5 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index EBioMedicine?
According to LetPub and DOAJ records, EBioMedicine is indexed in SCIE, Scopus and DOAJ.
Is EBioMedicine open access, and what is the APC?
EBioMedicine is a fully open-access journal. APC about USD 6,810.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .